BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026
I'm PortAI, I can summarize articles.
RBC Capital Markets reports a strong rebound in the biotech sector since April 2025, driven by clinical data and new drug launches. M&A activity is booming, with $101B in deals in 2025. The funding environment has improved, with successful IPOs and increased financing. Despite policy fears, regulatory volatility persists. RBC highlights Kymera Therapeutics, Apogee Therapeutics, Xenon Pharmaceuticals, and Ascendis Pharma as potential acquisition targets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments